Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Amicus Therapeutics (FOLD) over the last 14 years, with Sep 2025 value amounting to $33.0 million.

  • Amicus Therapeutics' Net Cash Flow rose 12.04% to $33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$59.7 million, marking a year-over-year decrease of 224.19%. This contributed to the annual value of -$29.3 million for FY2024, which is 132.36% down from last year.
  • As of Q3 2025, Amicus Therapeutics' Net Cash Flow stood at $33.0 million, which was up 201.03% from -$32.7 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Net Cash Flow ranged from a high of $212.0 million in Q3 2021 and a low of -$146.9 million during Q4 2022.
  • In the last 3 years, Amicus Therapeutics' Net Cash Flow had a median value of -$143,000 in 2024 and averaged $2.3 million.
  • Per our database at Business Quant, Amicus Therapeutics' Net Cash Flow surged by 417.32% in 2023 and then slumped by 22,769.93% in 2025.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Net Cash Flow stood at -$138.7 million in 2021, then dropped by 5.92% to -$146.9 million in 2022, then surged by 91.64% to -$12.3 million in 2023, then slumped by 88.88% to -$23.2 million in 2024, then rose by 12.04% to $33.0 million in 2025.
  • Its Net Cash Flow stands at $33.0 million for Q3 2025, versus -$32.7 million for Q2 2025 and -$36.8 million for Q1 2025.